...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: Design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies
【24h】

Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: Design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies

机译:具有显着选择性COX-2抑制作用的新型1- [4-(氨基磺酰基)苯基] -1H-1,2,4-三唑衍生物:设计,合成,分子对接,抗炎和致溃疡性研究

获取原文
获取原文并翻译 | 示例
           

摘要

A novel series of 1,2,4-triazole derivatives were synthesized and confirmed with different spectroscopic techniques. The prepared compounds exhibited remarkable anti-inflammatory activity comparable to that of indomethacin and celecoxib after 3 h. The tested compounds exhibited very low incidence of gastric ulceration compared to indomethacin. Most of the newly developed compounds showed excellent selectivity towards human COX-2 with selectivity indices (COX-1 IC_(50)/COX-2 IC_(50)) ranged from 62.5 to 2127. Docking studies results revealed that the highly selective tested compounds 6h and 6j showed lower CDOCKER energies, which means that they require less energy for proper interaction with the enzyme. The additional H-bonds with the oxygen of the amide and/or H of NH of the amide with the amino acid residues may be responsible for the higher binding affinity of this group of compounds towards COX-2.
机译:合成了一系列新的1,2,4-三唑衍生物,并用不同的光谱技术对其进行了确认。制备的化合物在3小时后显示出与消炎痛和塞来昔布相当的抗炎活性。与消炎痛相比,所测试的化合物表现出极低的胃溃疡发生率。大多数新开发的化合物对人COX-2表现出优异的选择性,选择性指数(COX-1 IC_(50)/ COX-2 IC_(50))介于62.5至2127之间。对接研究结果表明,经高度选择性测试的化合物6h和6j显示较低的CDOCKER能量,这意味着它们与该酶正确相互作用所需的能量更少。与酰胺的氧的另外的H键和/或与氨基酸残基的酰胺的NH的另外的H键可负责这组化合物对COX-2的更高的结合亲和力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号